Akebia Therapeutics dba Keryx Biopharmaceutials, Inc

FDA Regulatory Profile

Akebia Therapeutics dba Keryx Biopharmaceutials, Inc appears in FDA public data with 2 recalls, 0 510(k) clearances, 0 FDA inspections, and 0 compliance actions on record. Its most recent recall (D-0260-2021, Class III) was initiated on January 29, 2021.

Summary

Total Recalls
2
510(k) Clearances
0
Inspections
0
Compliance Actions
0

Recent Recalls

NumberClassProductDate
D-0260-2021Class IIIAuryxia (ferric citrate) tablets, 210 mg*, 200 tablets bottle, RX ONLY, Manufactured for and distribJanuary 29, 2021
D-0170-2021Class IIAuryxia (ferric citrate) tablets, 210 mg, 200-count bottles, Rx only, Manufactured for and distributDecember 9, 2020